Amelogenins and Systemic Inflammation After Periodontal Surgical Therapy (PERIOEMD-1)
Enamel Matrix Derivatives on Systemic Inflammation After Periodontal Surgical Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Pisa, Italy, 56126
- University Hospital of Pisa
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Good health
- No previous periodontal surgical treatment
- Indication for periodontal surgery (intrabony defects to be at least 4 mm deep)
- Ability to understand the study procedures and comply with them through the length of the study
Exclusion Criteria:
- Pregnancy, breast feeding or taking oral contraceptive (all non-drug contraceptives will be allowed)
- The need for antibiotic therapy to undergo periodontal therapy
- Chronic infections
- Systemic diseases
- Patients who report current smoking over 20 cigarettes per day or pipe or cigar
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Periodontal Surgery with EMD
A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed.
After carefully cleaning root dental surfaces, EMD was placed inside the infrabony periodontal defect.
Suture were placed to maintain wound stability.
|
After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques.
After flap elevation, careful removal of granulation tissues from the periodontal defects is performed.
Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
Other Names:
Application of Pref-Gel for 2 minutes and then the application on Enamel Matrix Derivatives on the surgically exposed root surface
Other Names:
|
|
Active Comparator: Periodontal Surgery
A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed.
Suture were placed to maintain wound stability.
|
After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques.
After flap elevation, careful removal of granulation tissues from the periodontal defects is performed.
Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of C Reactive Protein (CRP) at 24 hour
Time Frame: Collected at Baseline and 24 hours in order to calculate the changes
|
CRP analyzed though blood sampling.
Unit of measure: mg/L
|
Collected at Baseline and 24 hours in order to calculate the changes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose
Time Frame: Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
analyzed though blood sampling.
Unit of measure: mg/dL
|
Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
|
Cholesterol
Time Frame: Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
analyzed though blood sampling.
Unit of measure: mg/dL
|
Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
|
Triglycerides
Time Frame: Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
analyzed though blood sampling.
Unit of measure: mg/dL
|
Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
|
HDL Cholesterol
Time Frame: Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
analyzed though blood sampling.
Unit of measure: mg/dL
|
Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
|
LDL Cholesterol
Time Frame: Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
analyzed though blood sampling.
Unit of measure: mg/dL
|
Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
|
Fibrinogen
Time Frame: Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
analyzed though blood sampling.
Unit of measure: mg/dL
|
Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
|
D-Dimer
Time Frame: Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
analyzed though blood sampling.
Unit of measure: mg/L
|
Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
|
Cystatin C
Time Frame: Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
analyzed though blood sampling.
Unit of measure: mg/L
|
Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
|
C Reactive Protein (CRP)
Time Frame: Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
CRP analyzed though blood sampling.
Unit of measure: mg/L
|
Analyzed at Baseline, 24 hours, 1 week and 6 months after treatment
|
|
Clinical attachment level (CAL) at deepest site
Time Frame: Measured at Baseline and 6 months after treatment
|
Changes in CAL , measured orally through clinical examination.
Unit of measure: mm
|
Measured at Baseline and 6 months after treatment
|
|
Pocket probing depth (PPD) at deepest site
Time Frame: Measured at Baseline and 6 months after treatment
|
Changes in PPD , measured orally through clinical examination.
Unit of measure: mm
|
Measured at Baseline and 6 months after treatment
|
|
Recession of the gingival margin (REC)
Time Frame: Measured at Baseline and 6 months after treatment
|
Changes in REC, measured orally through clinical examination.
Unit of measure: mm
|
Measured at Baseline and 6 months after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 3649/13A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.